If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
23 March to 3 April The 3rd Battalion, 9th Marines and elements of the 1st Brigade, 5th Infantry Division launch Operation Montana Mauler against the PAVN 27th Regiment north of Firebase Fuller in Quảng Trị Province. The operation results in 271 PAVN killed, U.S. losses are 38 killed.
One milliliter (20 drops) of wintergreen oil is equivalent to about 1860 mg of aspirin, or almost six regular-strength adult aspirin tablets. Treatment is identical to the other salicylates. Early use of hemodialysis in conjunction with maximal supportive measures is encouraged in any significant ingestion of methyl salicylate.
==== Indications ==== Dronabinol, also known as tetrahydrocannabinol (THC), is a natural compound extracted from plants. It is available as Marinol® and Syndros®. It is used as an appetite stimulant in anorexia-associated weight loss in HIV/AIDS patients. An increase in patients' appetite and daily calorie intake with minimal improvement in weight and nausea is reported. Dronabinol is also indicated for chemotherapy-induced nausea and vomiting in cancer patients failing to respond to conventional antiemetics. Dronabinol is also used for cancer-related chronic pain in Europe.
Daphne Walker, singer (born 1930). 19 July – Lee Mummery, cricketer (Central Districts) (born 1935). 20 July – Jim Tomlin, artist, musician (Chants R&B), and art educator (Otago Polytechnic) (born 1940). 23 July – Kathryn Smits, Germanist (University of Auckland) (born 1935). 25 July – Ian Leggat, school teacher and university administrator, principal of Hagley High School (1971–1976) and Christchurch Boys' High School (1976–1988), University of Canterbury chancellor (1992–1998) (born 1929). 26 July Ian Carter, sociologist (University of Auckland) (born 1943). Keith Sorrenson, historian (University of Auckland), president of the Citizens' Association for Racial Equality (1971–1973), member of the Waitangi Tribunal (1986–2011) (born 1932). John Werry, child and adolescent psychiatrist (University of Auckland) (born 1931). 29 July – Sir Michael Hill, jeweller, businessman (Michael Hill Jeweller), and philanthropist (born 1938).
Sources: en.wikipedia.org
An X-ray room must be shielded on all sides with 1 mm lead equivalent shielding. Calcium silicate or solid brick masonry is recommended. A steel jamb should be used, not only because of the weight of the heavy shielding door but also because of the shielding; wooden frames must be shielded separately. The shielding door must be covered with a 1 mm thick lead foil and a lead glass window must be installed as a visual connection. A keyhole shall be avoided. All installations (sanitary or electrical), that interrupt the radiation protection, must be leaded ( § 20 § 20 Röntgenverordnung (röv_1987) [§ 20 X-ray Ordinance] (in German) and § Annex+2 Annex 2 (to § 8 para. 1 sentence 1 RöV) (röv_1987) (in German) Depending on the application, nuclear medicine requires even more extensive protective measures, up to and including concrete walls several meters thick. In addition, from December 31, 2018, when the latest amendments to Section 14 (1) No. 2b of the Radiation Protection Act § 14 Strahlenschutzgesetz – StrlSchG [Radiation Protection Act (StrlSchG)] (in German) come into force, an expert in medical physics for X-ray diagnostics and therapy must be consulted for the optimization and quality assurance of the application and for advice on radiation protection issues.
They proposed the name Parmotrema chinense, based on the assumption that Osbeck's specimen corresponded to the well-known species Parmotrema perlatum. However, this proposal was not universally adopted due to the lack of valid typification and the name's absence in the literature between 1757 and 1986.
Exon skipping is induced by eteplirsen, a charge-neutral, phosphorodiamidate morpholino oligomer (PMO) that selectively binds to exon 51 of dystrophin pre-mRNA, restoring the phase of the reading frame and enabling production of functional, but internally edited, dystrophin. The uncharged nature of the PMO helps make it resistant to biological degradation. This modified dystrophin protein produced by eteplirsen may cause a less severe form of dystrophinopathy, much like Becker muscular dystrophy. Eteplirsen's proposed mechanism of action is to bind to dystrophin pre-mRNA and alter the exon splicing of the RNA so that more almost full-length dystrophin is made. By increasing the quantity of an abnormal, but potentially functional, dystrophin protein, the objective is to slow or prevent the progression of DMD.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.